Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GlaxoSmithKline (GSK) and McLaren Group announce innovative strategic partnership
GSK announced it's formed a partnership with McLaren Group which will run initially until 2016 focusing on innovation and high-tech research
-
GlaxoSmithKline (GSK) commits $1 million in cervical cancer vaccine to new cooperative effort aimed at reducing deaths from women's cancers
GSK has committed $1 million in Cervarix, cervical cancer vaccine to the Pink Ribbon Red Ribbon partnership over the next five years.
-
GlaxoSmithKline and Amicus Therapeutics commence second phase III study of Amigal™ for Fabry disease
GlaxoSmithKline and Amicus Therapeutics commence second phase III study of Amigal™ for Fabry disease
-
GSK gives update on agreement with World Health Organization to support de-worming of school age children in endemic countries
First African countries, Togo and Rwanda, receive albendazole donations to scale-up school based de-worming programmes for children at risk.
-
Lapatinib clinical trial update
Review - Phase III study of lapatinib & trastuzumab in patients with HER2+ early stage breast cancer to continue trials without modification
-
Jens Eckstein named President of SR One, GSK’s venture healthcare group
Jens Eckstein has been named President of SR One, GSK's independent healthcare venture organisation, effective 1 October.
-
GlaxoSmithKline (GSK) shows sign of things to come at London 2012 Olympic and Paralympic Games
2012 provider, GSK, unveils sign celebrating its scientific contribution to the Games
-
GSK awarded contract by BARDA to support research on potential novel antibiotic
GSK & BARDA's contract to support the development of a potentially new antibiotic against hospital Gram negative and biothreat pathogens.
-
GSK takes minority stake in new spin out Autifony Therapeutics
GSK announced its wholly-owned subsidiary will receive 25.4% equity stake in Autifony Therapeutics Limited alongside other investors.
-
GSK and Impax announce positive topline results of ASCEND-PD Phase III study of IPX066 in Advanced Parkinson’s disease
IPX066 demonstrated statistically significant improvement over carbidopa-levodopa plus entacapone in reducing off time % during waking hours
-
GSK and Enigma Diagnostics announce collaboration on assay development and commercialisation of Enigma’s ML platform
GSK & Enigma announced agreements for the supply of Enigma ML system for respiratory tests for use on its real-time PCR technology platform.
-
Regulatory Update: GSK and XenoPort submit supplemental New Drug Application to FDA for Horizant™ in postherpetic neuralgia
GSK & XNPT announced sNDA submitted to FDA for approval of Horizant tablets for the management of PHN in adults.
-
Regulatory update – Stiefel, a GSK company, files NDA for tazarotene foam
Stiefel announced it's submitted a NDA to the FDA for tazarotene foam for the topical treatment of facial acne vulgaris in patients 12+.
-
GSK delivers strong Q2 performance with underlying sales growth* of 5%, increased pipeline visibility and dividend of 16p, up 7%
Full details of GSK's results for the second quarter of 2011 can be found in the
-
GlaxoSmithKline European regulatory update on Pandemrix™
GSK announced EMA's CHMP has recommended an update to the product label for the H1N1 influenza vaccine, Pandemrix.
-
GlaxoSmithKline and Human Genome Sciences receive European authorisation for Benlysta® (belimumab)
GSK & HSG announced, EC has granted marketing authorisation for Benlysta as therapy in patients with active autoantibody-positive SLE.
-
EU and US Regulatory Update - Votrient® (pazopanib)
GSK announced it's submitted a Marketing Authorisation Application to EMA for Votrient, the treatment of patients with advanced STR.
-
London 2012 partner, GlaxoSmithKline, shares scientific expertise with World Anti-Doping Agency to help fight against abuse of drugs in sport
GSK signed a long-term agreement with WADA helping create early detection methods for performance-enhancing medicines in sport.
-
GlaxoSmithKline receives new approval for Rotarix and significant new indication for Lamictal® (lamotrigine) in Japan
GSK rotavirus vaccine approved for use in babies Lamotrigine becomes the first treatment to be approved in Japan for adult bipolar disorder
-
GSK welcomes external scientists to diseases of the developing world research campus
GSK will provide support, expertise and facilities as part of our open innovation strategy to spur global collaboration in research